BioSpace News Archive

EyeGate Pharma today announced that it has been granted U.S. Patent No. 9,820,935, by the USPTO.

The leadership changes are a result of Bryan Hanson’s departure to become President and CEO of another public, medical technology company, effective today.

Yield10 Bioscience today announced the pricing of an underwritten public offering of units for gross proceeds of $12.6M, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience.

Under terms of the 18-month agreement, Chembio will receive up to $2.9M in funding from Astra.

Prior to joining as CFO, Sullivan was an observer on Apellis’ board of directors for nearly three years while he was a Partner at AJU IB Investment, a venture capital firm, where he led the firm’s investments in life sciences companies.

Xbrane Biopharma has signed a distribution agreement with BL&H for sales and marketing of Spherotide in South Korea. Xbrane will receive mid-single digit SEK million license fee for the exclusive rights to Spherotide in South Korea and Xbrane and BL&H will share the profits from sales. Timing of launch is expected to earliest 2019.

This SPA provides agreement that the Phase 3 protocol design, notably clinical endpoints, trial population and statistical analyses adequately address objectives that, if met, would form the primary basis of an efficacy claim in support of a regulatory submission for approval of intravenous citrulline for the prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric subjects undergoing surgery for congenital heart defects.

Success at growing tiny human stomachs in a lab dish. Discovering a way to shrink painful, disfiguring nerve tumors.

PAS and Allovate announce that they have signed an exclusive agreement to combine PAS’s simple and minimally invasive fingerstick allergy test and Allovate’s Allerdent.

Hemispherx Biopharma announced the posting of a letter to shareholders on its website, www.hemispherx.com, in which CEO Thomas K. Equels reviews corporate activities progress over the past nine months and outlines key objectives going forward.